



Finanziato  
dall'Unione europea  
NextGenerationEU



Ministero  
dell'Università  
e della Ricerca



Italiadomani  
PIANO NAZIONALE  
DI RIPRESA E RESILIENZA

HEALITALIA

# Spoke 1 – Holistic Nosology Personalised RNA-Oriented Medicine in Italy Novel Therapeutics (PROMINENT) – INT PASCALE



ISTITUTO NAZIONALE TUMORI  
IRCCS - Fondazione Pascale



V: Università  
degli Studi  
della Campania  
*Luigi Vanvitelli*

biogem



Finanziato  
dall'Unione europea  
NextGenerationEU



Ministero  
dell'Università  
e della Ricerca



Italiadomani  
PIANO NAZIONALE  
DI RIPRESA E RESILIENZA

HEALITALIA

## SPOKE 1: Holistic Nosology

*FROM PATIENTS TO MOLECULES & BACK*: Mapping the omics landscape of clinical to molecular environment, to identify, classify, and refine the phenotypes of multifactorial diseases.

**Spoke leader: University of Rome «Tor Vergata»**

**Titolo progetto: Personalised RNA-Oriented Medicine in Italy Novel Therapeutics (PROMINENT)**

N. partner	Denominazione/ragione sociale (per le imprese)	Dimensione di impresa (MP, PI, MI, GI) (solo per le imprese)
1 (Capofila)	Fondazione Human Technopole (FHT)	
2	Università della Campania "L. Vanvitelli"	
3	IRCCS INT Fondazione "G. Pascale" (INT – Pascale)	
4	Biogem scarl (Biogem)	MI

Finanziato dall'Unione europea NextGenerationEU


Ministero dell'Università e della Ricerca

Italiadomani  
PIANO NAZIONALE DI RIPRESA E RESILIENZA

HEAL ITALIA



A Comprehensive Cancer Center





6 Clinical DISEASE-ORIENTED Departments

3 Clinical Strategic Departments  
1 Functional Dept

Department of TRANSLATIONAL RESERACH

2 Administrative and Strategic Services Departments

<https://newportal.istitutotumori.na.it/>



The **National Cancer Institute – IRCCS "Fondazione Pascale"** in Naples, is a leading public research and healthcare facility based in Southern Italy.

The **mission** of the Pascale Institute is to lead advancements in oncology through a combination of cutting-edge research, innovative clinical practice, and comprehensive patient care.

The IRCCS INT Pascale **aims** to achieve excellence in the field of oncology and to identify new and suitable directions in the field of prevention, diagnosis and treatment of tumor pathologies through translational & clinical research and technological and management innovation, shifting the centrality from the disease to the patient.



Finanziato  
dall'Unione europea  
NextGenerationEU



Ministero  
dell'Università  
e della Ricerca



Italiadomani  
PIANO NAZIONALE  
DI RIPRESA E RESILIENZA

HEAL ITALIA

## PROMINENT GOAL

The project aims to develop **innovative, cost-effective**, and evidence-based **non-invasive diagnostic pathways** for faster, earlier, more accurate, accessible, and affordable prediction, detection, and monitoring of monogenic (rare), polygenic (cardiovascular and metabolic) diseases, and cancer, while identifying effective and **innovative therapeutic approaches**.

1. Precision Medicine: the common soil hypothesis and the Moli-sani studies and other cohorts.
2. Genomics, Phenomics and Biomarkers.
3. Metabolome mapping from mouse to Moli-sani sub-cohorts and development of new therapeutic targets.



Finanziato  
dall'Unione europea  
NextGenerationEU



Ministero  
dell'Università  
e della Ricerca



Italiadomani  
PIANO NAZIONALE  
DI RIPRESA E RESILIENZA

HEALITALIA

## Contribution to the Research Program of the Spoke 1 – INT PASCALE

- **Design of the clinical study** and definition of the **procedure for the recruitment** of healthy subjects (50) and patients affected by various oncological diseases, including colorectal cancer (250), breast cancer (500), and head and neck cancer (50), within the framework of the PROMINENT project
- Evaluate the plasma metabolomic and miRNomic profiles in collaboration with the University of Campania 'L. Vanvitelli'
- *In vitro* validation of **identified miRNAs**
- Correlation between **metabolomics/miRNomic profiles and clinical data**